GSK (GSK) News Today

GSK plc (GSK) saw its stock influenced by a mix of analyst rating updates and a key FDA approval. Investors are weighing the bullish vaccine news against cautious and negative broker views.

• Positive Sentiment: Shore Capital reiterated a Buy rating on GSK with a GBX 2,000 ($26.86) price target, reflecting confidence in the company’s growth prospects. GSK (LON:GSK) Earns Buy Rating from Shore Capital
• Positive Sentiment: The US FDA approved GSK’s Shingrix in a new prefilled syringe format, enhancing convenience and potentially boosting uptake of the blockbuster shingles vaccine. GSK wins FDA nod for new shingles vaccine format
• Neutral Sentiment: Berenberg Bank reaffirmed its Hold rating on GSK and set a GBX 1,600 ($21.49) target price, maintaining a neutral stance on near-term performance. Berenberg Bank Reiterates "Hold" Rating for GSK
• Negative Sentiment: Bank of America maintained a Sell rating on GSK with a price target of p1,510, highlighting concerns around the performance of its Blenrep oncology asset. BofA Maintains a Sell Rating on GSK plc (GSK), Sets a PT of p1,510
• Negative Sentiment: JPMorgan Chase & Co. reaffirmed its Underweight rating on GSK, suggesting limited upside relative to sector peers. GSK's "Underweight" Rating Reaffirmed at JPMorgan Chase & Co.

Investors should balance the positive regulatory milestone for Shingrix against mixed broker sentiment when evaluating GSK’s near-term outlook.